Acquisition by Shin Park of 37523 shares of MagnaChip Semiconductor subject to Rule 16b-3
| 226950 Stock | 21,100 1,000.00 4.98% |
About 55% of OliX PharmaceuticalsI's investors are presently thinking to get in. The analysis of current outlook of investing in OliX PharmaceuticalsInc suggests that some traders are interested regarding OliX PharmaceuticalsI's prospects. The current market sentiment, together with OliX PharmaceuticalsI's historical and current headlines, can help investors time the market. In addition, many technical investors use OliX PharmaceuticalsInc stock news signals to limit their universe of possible portfolio assets.
OliX |
Filed transaction by Magnachip Semiconductor C officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
OliX PharmaceuticalsI Fundamental Analysis
We analyze OliX PharmaceuticalsI's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OliX PharmaceuticalsI using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OliX PharmaceuticalsI based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
OliX PharmaceuticalsI is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
OliX PharmaceuticalsInc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OliX PharmaceuticalsI stock to make a market-neutral strategy. Peer analysis of OliX PharmaceuticalsI could also be used in its relative valuation, which is a method of valuing OliX PharmaceuticalsI by comparing valuation metrics with similar companies.
Peers
OliX PharmaceuticalsI Related Equities
| 235980 | MedPacto | 5.22 | ||||
| 334970 | Prestige Biologics | 3.80 | ||||
| 207940 | Samsung Biologics | 2.58 | ||||
| 326030 | Sk Biopharmaceutica | 2.25 | ||||
| 298380 | ABL Bio | 1.50 | ||||
| 144510 | Green Cross | 1.18 | ||||
| 086890 | ISU Abxis | 0.10 |
Complementary Tools for OliX Stock analysis
When running OliX PharmaceuticalsI's price analysis, check to measure OliX PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OliX PharmaceuticalsI is operating at the current time. Most of OliX PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of OliX PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OliX PharmaceuticalsI's price. Additionally, you may evaluate how the addition of OliX PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |